PPARγ agonist rosiglitazone alters the temporal and spatial distribution of inflammation during abdominal aortic aneurysm formation

Wang,Wen‑Da; Sun,Rui; Chen,Yue‑Xin

doi:10.3892/mmr.2018.9311

PPARγ agonist rosiglitazone alters the temporal and spatial distribution of inflammation during abdominal aortic aneurysm formation

Authors:
- Wen‑Da Wang
- Rui Sun
- Yue‑Xin Chen
View Affiliations

Affiliations: Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China
Published online on: July 24, 2018 https://doi.org/10.3892/mmr.2018.9311
Pages: 3421-3428

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Research into inflammation during abdominal aortic aneurysm (AAA) formation remains inconclusive. The present study aimed to demonstrate the temporal and spatial distribution of inflammatory cytokines, and to confirm the effect of peroxisome proliferator‑activated receptor γ (PPARγ) on the incidence of AAA formation and the distribution of inflammation in the disease process. Male apolipoprotein E‑/‑ mice were randomly divided into eight groups: Angiotensin II (Ang‑II)‑only 7, 14, 21, 28 and 42 days groups, Ang‑II with rosiglitazone (RGZ) 28 and 42 days groups, and the saline control 42 days group. The early stage was defined as between 7 and 21 days, and the late stage as between 28 and 42 days. Incidences of early rupture and late rupture, aneurysm formation and the maximum diameters of the aorta were recorded. Suprarenal abdominal aortic tissues were collected for histological analysis, and western blotting was performed to reveal the distribution of inflammation. Treatment with Ang‑II caused a significant dilation of the aorta in the late stage; however, this was not observed in the early stage. RGZ reduced the maximum diameters in the late stage. With the pathological process alterations, the inflammatory type shifted. Regarding temporal distribution, the tumor necrosis factor (TNF)‑α expression level was increased over time, and the interleukin (IL)‑10 expression level significantly decreased. When considering the spatial distribution, TNF‑α was expressed dominantly in the aneurysmal body and IL‑10 was dominant in the aneurysmal neck in the late stage. The PPARγ agonist RGZ may reduce the expression of TNF‑α in the late stage and increase the expression level of IL‑10, maintaining the TNF‑α or IL‑10 expression levels at the same levels as in the early stage. Aortic inflammation during AAA formation is dynamic. Protective anti‑inflammatory cytokines are upregulated in the early ‘compensatory stage’; however, pro‑inflammatory cytokines are dominant in the late ‘decompensatory stage’. PPARγ is likely to continue to upregulate the expression of anti‑inflammatory cytokines, extend the ‘compensatory stage’, and decelerate the process of AAA development and rupture.

View Figures

View References

1	Singh K, Bønaa KH, Jacobsen BK, Bjørk L and Solberg S: Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study: The Tromsø study. Am J Epidemiol. 154:236–244. 2001. View Article : Google Scholar : PubMed/NCBI
2	Eagleton MJ: Inflammation in abdominal aortic aneurysms: Cellular infiltrate and cytokine profiles. Vascular. 20:278–283. 2012. View Article : Google Scholar : PubMed/NCBI
3	Schönbeck U, Sukhova GK, Gerdes N and Libby P: T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm. Am J Pathol. 161:499–506. 2002. View Article : Google Scholar : PubMed/NCBI
4	Xiong W, Zhao Y, Prall A, Greiner TC and Baxter BT: Key roles of CD4+ T cells and IFN-gamma in the development of abdominal aortic aneurysms in a murine model. J Immunol. 172:2607–2612. 2004. View Article : Google Scholar : PubMed/NCBI
5	Shimizu K, Libby P and Mitchell RN: Local cytokine environments drive aneurysm formation in allografted aortas. Trends Cardiovasc Med. 15:142–148. 2005. View Article : Google Scholar : PubMed/NCBI
6	Shimizu K, Mitchell RN and Libby P: Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 26:987–994. 2006. View Article : Google Scholar : PubMed/NCBI
7	Jones A, Deb R, Torsney E, Howe F, Dunkley M, Gnaneswaran Y, Gaze D, Nasr H, Loftus IM, Thompson MM and Cockerill GW: Rosiglitazone reduces the development and rupture of experimental aortic aneurysms. Circulation. 119:3125–3132. 2009. View Article : Google Scholar : PubMed/NCBI
8	Croasdell A, Duffney PF, Kim N, Lacy SH, Sime PJ and Phipps RP: PPARγ and the innate immune system mediate the resolution of inflammation. PPAR Res. 2015:5496912015. View Article : Google Scholar : PubMed/NCBI
9	Motoki T, Kurobe H, Hirata Y, Nakayama T, Kinoshita H, Rocco KA, Sogabe H, Hori T, Sata M and Kitagawa T: PPAR-γ agonist attenuates inflammation in aortic aneurysm patients. Gen Thorac Cardiovasc Surg. 63:565–571. 2015. View Article : Google Scholar : PubMed/NCBI
10	Celinski K, Dworzanski T, Korolczuk A, Piasecki R, Slomka M, Madro A and Fornal R: Effects of peroxisome proliferator-activated receptors-gamma ligands on dextran sodium sulphate-induced colitis in rats. J Physiol Pharmacol. 62:347–356. 2011.PubMed/NCBI
11	Pisanu A, Lecca D, Mulas G, Wardas J, Simbula G, Spiga S and Carta AR: Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease. Neurobiol Dis. 71:280–291. 2014. View Article : Google Scholar : PubMed/NCBI
12	Golledge J, Cullen B, Rush C, Moran CS, Secomb E, Wood F, Daugherty A, Campbell JH and Norman PE: Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm. Atherosclerosis. 210:51–56. 2010. View Article : Google Scholar : PubMed/NCBI
13	Hasan DM, Starke RM, Gu H, Wilson K, Chu Y, Chalouhi N, Heistad DD, Faraci FM and Sigmund CD: Smooth muscle peroxisome proliferator-activated receptor γ plays a critical role in formation and rupture of cerebral aneurysms in mice in vivo. Hypertension. 66:211–220. 2015. View Article : Google Scholar : PubMed/NCBI
14	Apgar JM, Juarranz A, Espada J, Villanueva A, Cañete M and Stockert JC: Fluorescence microscopy of rat embryo sections stained with haematoxylin-eosin and Masson's trichrome method. J Microsc. 191:20–27. 1998. View Article : Google Scholar : PubMed/NCBI
15	Hackam DG, Thiruchelvam D and Redelmeier DA: Angiotensin-converting enzyme inhibitors and aortic rupture: A population-based case-control study. Lancet. 368:659–665. 2006. View Article : Google Scholar : PubMed/NCBI
16	Jones GT, Thompson AR, van Bockxmeer FM, Hafez H, Cooper JA, Golledge J, Humphries SE, Norman PE and van Rij AM: Angiotensin II type 1 receptor 1166C polymorphism is associated with abdominal aortic aneurysm in three independent cohorts. Arterioscler Thromb Vasc Biol. 28:764–770. 2008. View Article : Google Scholar : PubMed/NCBI
17	Daugherty A, Manning MW and Cassis LA: Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 105:1605–1612. 2000. View Article : Google Scholar : PubMed/NCBI
18	Daugherty A, Cassis LA and Lu H: Complex pathologies of angiotensin II-induced abdominal aortic aneurysms. J Zhejiang Univ Sci B. 12:624–628. 2011. View Article : Google Scholar : PubMed/NCBI
19	Chobanian AV and Alexander RW: Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications. Arch Intern Med. 156:1952–1956. 1996. View Article : Google Scholar : PubMed/NCBI
20	Kim JA, Berliner JA and Nadler JL: Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun. 226:862–868. 1996. View Article : Google Scholar : PubMed/NCBI
21	Yanagitani Y, Rakugi H, Okamura A, Moriguchi K, Takiuchi S, Ohishi M, Suzuki K, Higaki J and Ogihara T: Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension. 33:335–339. 1999. View Article : Google Scholar : PubMed/NCBI
22	Cassis LA, Gupte M, Thayer S, Zhang X, Charnigo R, Howatt DA, Rateri DL and Daugherty A: ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice. Am J Physiol Heart Circ Physiol. 296:H1660–H1665. 2009. View Article : Google Scholar : PubMed/NCBI
23	Manning MW, Cassi LA, Huang J, Szilvassy SJ and Daugherty A: Abdominal aortic aneurysms: Fresh insights from a novel animal model of the disease. Vasc Med. 7:45–54. 2002. View Article : Google Scholar : PubMed/NCBI
24	Lu H, Rateri DL, Bruemmer D, Cassis LA and Daugherty A: Involvement of the renin-angiotensin system in abdominal and thoracic aortic aneurysms. Clin Sci (Lond). 123:531–543. 2012. View Article : Google Scholar : PubMed/NCBI
25	Cassis LA, Rateri DL, Lu H and Daugherty A: Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol. 27:380–386. 2007. View Article : Google Scholar : PubMed/NCBI
26	Peshkova IO, Schaefer G and Koltsova EK: Atherosclerosis and aortic aneurysm-is inflammation a common denominator? FEBS J. 283:1636–1652. 2016. View Article : Google Scholar : PubMed/NCBI
27	King VL, Lin AY, Kristo F, Anderson TJ, Ahluwalia N, Hardy GJ, Owens AP III, Howatt DA, Shen D, Tager AM, et al: Interferon-gamma and the interferon-inducible chemokine CXCL10 protect against aneurysm formation and rupture. Circulation. 119:426–435. 2009. View Article : Google Scholar : PubMed/NCBI
28	Xiong W, MacTaggart J, Knispel R, Worth J, Persidsky Y and Baxter BT: Blocking TNF-alpha attenuates aneurysm formation in a murine model. J Immunol. 183:2741–2746. 2009. View Article : Google Scholar : PubMed/NCBI
29	Xanthoulea S, Thelen M, Pöttgens C, Gijbels MJ, Lutgens E and de Winther MP: Absence of p55 TNF receptor reduces atherosclerosis, but has no major effect on angiotensin II induced aneurysms in LDL receptor deficient mice. PLoS One. 4:e61132009. View Article : Google Scholar : PubMed/NCBI
30	Davenport P and Tipping PG: The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol. 163:1117–1125. 2003. View Article : Google Scholar : PubMed/NCBI
31	Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, Palinski W, Curtiss LK, Corr M and Witztum JL: IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest. 114:427–437. 2004. View Article : Google Scholar : PubMed/NCBI
32	Xu J, Ehrman B, Graham LM and Eagleton MJ: Interleukin-5 is a potential mediator of angiotensin II-induced aneurysm formation in apolipoprotein E knockout mice. J Surg Res. 178:512–518. 2012. View Article : Google Scholar : PubMed/NCBI
33	Shimizu K, Shichiri M, Libby P, Lee RT and Mitchell RN: Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest. 114:300–308. 2004. View Article : Google Scholar : PubMed/NCBI
34	Ait-Oufella H, Wang Y, Herbin O, Bourcier S, Potteaux S, Joffre J, Loyer X, Ponnuswamy P, Esposito B, Dalloz M, et al: Natural regulatory T cells limit angiotensin II-induced aneurysm formation and rupture in mice. Arterioscler Thromb Vasc Biol. 33:2374–2379. 2013. View Article : Google Scholar : PubMed/NCBI
35	de Araújo RF Jr, Reinaldo MP, Brito GA, Cavalcanti Pde F, Freire MA, de Medeiros CA and de Araújo AA: Olmesartan decreased levels of IL-1β and TNF-α, down-regulated MMP-2, MMP-9, COX-2, RANK/RANKL and up-regulated SOCs-1 in an intestinal mucositis model. PLoS One. 9:e1149232014. View Article : Google Scholar : PubMed/NCBI
36	Shimizu K, Libby P and Mitchell RN: Local cytokine environments drive aneurysm formation in allografted aortas. Trends Cardiovasc Med. 15:142–148. 2005. View Article : Google Scholar : PubMed/NCBI
37	Celinski K, Dworzanski T, Korolczuk A, Piasecki R, Slomka M, Madro A and Fornal R: Effects of peroxisome proliferator-activated receptors-gamma ligands on dextran sodium sulphate-induced colitis in rats. J Physiol Pharmacol. 62:347–356. 2011.PubMed/NCBI
38	Pisanu A, Lecca D, Mulas G, Wardas J, Simbula G, Spiga S and Carta AR: Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease. Neurobiol Dis. 71:280–291. 2014. View Article : Google Scholar : PubMed/NCBI
39	Chawla A: Control of macrophage activation and function by PPARs. Circ Res. 106:1559–1569. 2010. View Article : Google Scholar : PubMed/NCBI